<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05108363</url>
  </required_header>
  <id_info>
    <org_study_id>CGM-OSA</org_study_id>
    <nct_id>NCT05108363</nct_id>
  </id_info>
  <brief_title>Effect of Obstructive Sleep Apnea on Glucose Control and Cognitive Function</brief_title>
  <official_title>Effect of Obstructive Sleep Apnea on Glucose Control and Cognitive Function - a Substudy of 'Continuous Glucose Monitoring as an Adjunct to Lifestyle Modification in Individuals With Impaired Glucose Tolerance: a Randomised Controlled Trial'</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea (OSA) may contribute to altered cognitive function in patients&#xD;
      suffering from severe OSA. And lifestyle modification program may improve the cognitive&#xD;
      function after 6 months of therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>And lifestyle modification program for 6 months of therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Montreal Cognitive Assessment (MoCA) score</measure>
    <time_frame>12 months</time_frame>
    <description>Scores on the MoCA range from zero to 30, with a score of 26 and higher generally considered normal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of apnea-hypopnea index</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cognitive Change</condition>
  <arm_group>
    <arm_group_label>Lifestyle modification program</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with obstructive sleep apnea and prediabetes will have lifestyle modification program for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle modification program</intervention_name>
    <description>Participants will attend dietary consultation sessions weekly in the first 4 months during the intensive phase , and monthly in the subsequent 8 months in the maintenance phase of LMP either face-to-face or via telephone. Participants will be given an individualized menu plan aiming at achieving a varied balanced diet with an emphasis on fiber intake and moderate-carbohydrate, low-fat, low-glycemic index products in appropriate portions. The diet will aim for a calorie reduction of 10-20%, at least 10% body weight reduction or body mass index less than 23 kg/m2.Participants will see an exercise instructor a minimum of four times starting at the 2nd month. The exercise instructor will design a suitable exercise regime. Participants will first be advised to increase daily physical activities or to do moderate intensity aerobic exercise, with the goal of 30 minutes for 3 to 5 days a week.</description>
    <arm_group_label>Lifestyle modification program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI â‰¥ 25kg/m2&#xD;
&#xD;
          -  impaired glucose tolerance which defined as plasma glucose at the range of 7.8 and 11&#xD;
             mmol/l 2 hours after 75g oral glucose solution intake,&#xD;
&#xD;
          -  willing to participate in lifestyle modification program&#xD;
&#xD;
          -  and capable of using continuous glucose monitoring (CGM) as judged by investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lactating or pregnant,&#xD;
&#xD;
          2. known diabetes, current or previous use of glucose lowering drug&#xD;
&#xD;
          3. current participation in other weight loss or lifestyle interventions, or use of&#xD;
             weight loss drugs,&#xD;
&#xD;
          4. current use of steroids&#xD;
&#xD;
          5. uncontrolled thyrotoxicosis&#xD;
&#xD;
          6. allergy to medical grade adhesives&#xD;
&#xD;
          7. known obstructive sleep apnea on continuous positive airway pressure therapy&#xD;
&#xD;
          8. symptoms of cognitive deterioration (according to the Hong Kong Montreal Cognitive&#xD;
             Assessment (HK-MoCA) at the score of &lt;21)&#xD;
&#xD;
          9. predominant central sleep apnea&#xD;
&#xD;
         10. uncontrolled hypertension (blood pressure &gt;140/90mmHg) or requiring more than two&#xD;
             anti-hypertensive medication&#xD;
&#xD;
         11. history of stroke or brain injury,&#xD;
&#xD;
         12. unstable cardiovascular disease (e.g. recent unstable angina or myocardial infarction&#xD;
             within the previous 6 months or severe left ventricular failure; neuromuscular disease&#xD;
             affecting or potentially affecting respiratory muscles; moderate to severe respiratory&#xD;
             disease (i.e. breathlessness affecting activities of daily living) or documented&#xD;
             hypoxemia or awake SaO2 &lt;92%)&#xD;
&#xD;
         13. psychiatric disease that limits the ability to give informed consent or complete the&#xD;
             study&#xD;
&#xD;
         14. Use of psychoactive medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanna Ng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susanna SS Ng</last_name>
    <phone>35052211</phone>
    <email>ssng@cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Susanna SS Ng</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

